In addition, targeting the HER2 receptor helps clinicians monitor the efficacy of HER2-targeted therapy in patients and facilitates stratified patient studies, laying a solid foundation for the integration of ovarian cancer diagnosis and treatment. This evidence concerns the gene ERBB2 and ovarian carcinoma.